S. Takashima et al., Parotid gland lesions: Diagnosis of malignancy with MRI and flow cytometric DNA analysis and cytology in fine-needle aspiration biopsy, HEAD NECK, 21(1), 1999, pp. 43-51
Citations number
22
Categorie Soggetti
Otolaryngology
Journal title
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Background. The purpose of this study was to assess the capability of magne
tic resonance imaging (MRI) and cytology and flow cytometric (FCM) deoxyrib
onucleic acid (DNA) analysis in fine-needle aspiration biopsy (FNAB)-derive
d materials for diagnosing malignancy of the parotid lesions and the effica
cy of FCM analysis in FNAB.
Methods. Magnetic resonance imaging findings and FCM results (ploidy and S
+ G2 + M phases [S + G2M] fraction) and cytology in FNAB-derived materials
in 26 patients with 26 parotid lesions (12 benign lesions, 14 malignancies)
were assessed for predicting malignancy. Flow cytometric results in aspira
tes were compared with those in surgically resected tissues.
Results. When a single predictor was used, cytology (92% accuracy) was most
accurate for malignancy, followed by ill-defined margin (88% accuracy) and
aneuploidy (88% accuracy). The combination of FCM and cytology raised the
rate of sufficient materials from 92% to 100% and accuracy from 92% to 96%
compared with cytology alone. The same highest accuracy (96%) was obtained
with the combination of the ill-defined margin or other findings such as cy
tology, aneuploidy, or a high (S + G2M) fraction (6% <). Deoxyribonucleic a
cid ploidy in the FNAB showed full agreement with that in the surgical spec
imens. Receiver operating characteristic curves showed that the diagnosis o
f malignancy with (S + G2M) fraction in FNAB was superior to that in surgic
al specimens, but no significant difference was noted.
Conclusions. A combination of MRI findings, cytology, and FCM results is op
timal for diagnosing malignancies of the parotid lesions, and FNAB may repl
ace the surgical specimens in FCM analysis. (C) 1999 John Wiley & Sons, Inc
.